Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values)
(Safety Population)

Subject ID/Rando Number: }

Treatment: ●●●● Treatment A  ●●●● Treatment B  ●●●● Treatment C

0: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/ep/blinded/e210898_merc/stats/versioncontrol/primary/scripts/program/moin/TRL programs/Figures/Figure 15.4.2.11.sas
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Randon Number:

Treatment: •••• Treatment A  ●●●●● Treatment B  ★★★★ Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

/project243p0/02linded/021099.merq/state/versioncontrol/primary/scripts/program/main/YKL programs/Figures/Figure
15.4.2.11.sas
Subject 13/Number:

Treatment: --- Treatment B

8: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

/project2/ep/blinded/s210008_merc/stats/verncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.11.sas
Levothyroxine Dosage Form Proportion: Solutions (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Total T3 (ng/mL)

0 0.4 0.8 1.2 1.6

- 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50

Time Point (h)

Treatment: ●●● Treatment A □□□□□□□□□ Treatment B ▲▲▲▲▲▲▲▲▲ Treatment C

0: Subjects excluded from PK Population
Treatment A: 12 tablets of 50 µg of levothyroxine, Treatment B: 6 tablets of 100 µg of levothyroxine,
Treatment C: 3 tablets of 200 µg of levothyroxine.
/project24/wp/blinded/e21089_merc/stats/versioncontrol/primary/scripts/program/main/Israel programs/Figures/figure 15.4.2.11.sas

10REV2014 00:20

Document No:0906b6b6b898b89f1.0 CONFIDENTIAL INFORMATION 602/638
Levothyroxine Dosage Form Proportions

EMR 200125-002 Page 603 of 658

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (N=Total N=50)

[Graph showing concentration-time profiles for individual subjects with treatments A, B, and C.]

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.

/project244/gp/blinded/n210898_merco/stats/versioncontrol/primary/scripts/program/main/TWL programs/Figures/Figure 15.4.2.11.rss

Document No:9000056885905v1.0 CONFIDENTIAL INFORMATION 603858
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ■ Treatment A ▼ Treatment B ▲ Treatment C

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Document No. [Redacted] 604/008

CONFIDENTIAL INFORMATION
Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments]

- Treatment A: 12 tablets of 50 mg of levothyroxine
- Treatment B: 6 tablets of 100 mg of levothyroxine
- Treatment C: 3 tablets of 200 mg of levothyroxine

Subjects excluded from PK population:
- Treatment A: 3 tablets of 50 mg of levothyroxine
- Treatment B: 1 tablet of 100 mg of levothyroxine
- Treatment C: 1 tablet of 200 mg of levothyroxine

/Project/Abstract/2101898_Merc/Stats/script/primary/scripts/program/nca/TFL programs/figures/figure

Document No. 09054858
CONFIDENTIAL INFORMATION

EMR200125-002 665668
Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●●● Treatment A  ● ●● Treatment B  ●●●● Treatment C

8: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine;
Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine.

/project/ep/blinded/e216998_merc/stats/versioncontrol/primary/scripts/program/main/TL programs/figures/figure15_4_2_11.sas

Document No.0500hade08364hFr10 CONFIDENTIAL INFORMATION 06/26
Levothyroxine Dosage Form Proportion: \( \text{ions (50 \mu g, 100 \mu g, and 200 \mu g Tablets) in Fasted State} \)

Figure 15.4.2.11 Concentration-Time Profiles: Individual Concentration versus Actual Time in Linear Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●● Treatment A  ● Treatment B  ■■ Treatment C

9: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 \mu g of levothyroxine; Treatment B: 6 tablets of 100 \mu g of levothyroxine;
Treatment C: 3 tablets of 200 \mu g of levothyroxine.

/project/34/ap/hl/med/210/999_parc/stats/primary/scripts/program/main/TL programs/figures/Figure 15.4.2.11.sas
13DEC2014 00:20

CONFIDENTIAL
INFORMATION

Document No:05009b8e8085b9f1.0  608/658
Levothyroxine Dosage Form Properties: Ehas (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

Treatment: ●●● Treatment A ○○○ Treatment B ▲▲▲ Treatment C

0: Subjects excluded from FR Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 9 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.3

/project24/op/blinded/k210895_merc/stats/versioncontrol/primary/scripts/program/main/TVL programs/Figures/figure 15.4.2.12.sas
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-logarithmic Scale (for total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

- Treatment A: 12 tablets of 10 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Source: listing 16.2.3.3
Levothyroxine Dosage Form Preference

EMR 200125-002

Emphasis State

EMR200125-002 Page 611 of 658

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing Concentration-Time Profiles]

- : Subjects excluded from SW Populations:
  Treatment A: 12 tablets of 50 mg of levothyroxine;
  Treatment B: 6 tablets of 100 mg of levothyroxine;
  Treatment C: 3 tablets of 200 mg of levothyroxine.

Source: listing 16.2.5.3

/project24/ep/blindev/e210099_merc/stats/versioncontrol/primary/scripts/program/main/T3L programs/Figures/figure

15.4.2.12.sas

Document No.09080b268085806v1.0

CONFIDENTIAL INFORMATION
Levothyroxine Dosage Form Proportions: Tablets (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) [Safety Population]

Subject ID/Random Number: ""

Treatment: Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 15.2.5.3

/project24/per/glinded/a210958_mecr/stats/versioncontrol/primary/scripts/program/main/ML programs/Figures/Figure 15.4.2.12.sas

Document No.8900086020869v1.9 CONFIDENTIAL INFORMATION 6/2/19
Levothyroxine Dosage Form Proportionals
EMR 200125-002
Merck Serono
EMR 200125-002 Page 613 of 658

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for levothyroxine dosage forms. The graph plots concentration (T3 in mg/mL) against time (h) with different treatments indicated.]

- Treatment 1: 3 tablets of 50 μg of levothyroxine
- Treatment 2: 6 tablets of 100 μg of levothyroxine
- Treatment 3: 3 tablets of 200 μg of levothyroxine

Source: Listing 16.2.3.3

/project24/wp/blinded/2710898_merc/stats/versioncontrol/primary/scripts/program/main/TTL_programs/Figures/Figure 15.4.2.12.sas

10DEC2014 00:20

Document No.09006bbe808d9efv1.0
CONFIDENTIAL INFORMATION
6154658
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Subjects included in PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 18.3.6.3

/project24/op/blinded/c210899/marc/stats/versioncontrol/primary/scripts/program/xms/GT/programs/Figures/figure
15.4.2.12.sas

10/02/2014 06:20

Document No.690069re0015sbof/v1.0
CONFIDENTIAL
INFORMATION

EMR 200125-002 Page 614 of 658

Merk Serono
EMR 200125-002
Page 6 of 42
Confidential

Levothyroxine Dosage Form Proportion: (50 μg, 100 μg, and 200 μg Tablets) in Fasted State
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

Treatment: ●●● Treatment A  ▲▲▲ Treatment B  ■■■ Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.3

/project2/ep/blinded/0210899_mofo/stats/control/primary/scripts/program/main/TL_program/Figures/Figure 15.4.2.12.xls

13DEC2014 03:20
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Rando Number:

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

8 subjects excluded from PK Population

Source: Listing 16.2.5.3

/project24/sandbox/0210398_mapro/stats/versioncontrol/primary/scripts/program/main/VFL_programs/Figures/Figure 15.4.2.12.sas

10DEC2014 00:20

Document No. 0090012299 00:20

CONFIDENTIAL INFORMATION
Levothyroxine Dosage Form Proportions: (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Rando Number:

- Treatment A
- Treatment B
- Treatment C

Subjects excluded from FE Population:
- Treatment A: 12 tablets of 50 µg of Levothyroxine
- Treatment B: 6 tablets of 100 µg of Levothyroxine
- Treatment C: 3 tablets of 200 µg of Levothyroxine

Source: Listing 16.2.5.3

/project24/ep/blinded/s210896_more/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/15.4.2.12.sas

Document No:9906b9e905ba9f01.0

CONFIDENTIAL INFORMATION

617658
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

- Treatment: ●●●● Treatment A  ●●●● Treatment B  •••• Treatment C

- Subjects excluded from 90% Population:
  Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.5.3

/project24/sb/k1indac/210898_merc/stats/versioncontrol/primary/scripts/program/main/TLT programs/Figures/Figure 15.4.2.12.sos

Document No.090008be80859b9fv1.0 CONFIDENTIAL INFORMATION 618658
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Time Point (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment A</td>
<td>0, 1, 2, 4, 6</td>
</tr>
<tr>
<td>Treatment B</td>
<td>0, 1, 2, 4, 6</td>
</tr>
<tr>
<td>Treatment C</td>
<td>0, 1, 2, 4, 6</td>
</tr>
</tbody>
</table>

# Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine
Treatment B: 6 tablets of 100 µg of levothyroxine
Treatment C: 3 tablets of 200 µg of levothyroxine

Source: Listing 16.2.5.3

/project76mph/blinded/v316898_merc/stats/versioncontrol/primary/scripts/program/main/WL programs/figures/figure 15.4.2.12.msn

Document No. 000098980898

EMR 200125-002 Page 619 of 658
Levothyroxine Dosage Form Proportion \( \text{ions} (50 \, \mu\text{g}, 100 \, \mu\text{g}, \text{and} 200 \, \mu\text{g} \, \text{Tablets}) \) in Fasted State

EMR 200125-002

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T<sub>1</sub> values) (Safety Population)

Subject ID/Randon Number:

![Graph showing concentration-time profiles for treatments A, B, and C.](image)

9: Subjects excluded from PK Population:
- Treatment A: 12 tablets of 50 \( \mu\text{g} \) of levothyroxine
- Treatment B: 6 tablets of 100 \( \mu\text{g} \) of levothyroxine
- Treatment C: 3 tablets of 200 \( \mu\text{g} \) of levothyroxine

Source: Listing 15.2.1.3

/project24/ap/blinded/010828_mart/sta/versioncontrol/primary/scripts/program/main/CFE programs/Figures/Figure 15.4.2.12.xxx

108282014 00:20
Levothyroxine Dosage Form Properties: EMR 200125-002 (Subjects 50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph](image)

- Treatment: ●●● Treatment A  ◆◆◆ Treatment B  ▲▲▲ Treatment C

1: Subjects excluded from PK Population:
Treatment A: 32 tablets of 50 μg of levothyroxine. Treatment B: 6 tablets of 100 μg of levothyroxine.
Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: Listing 16.2.5.3

/project26/rp/blinded/e210898_herc/stats/vmsynccontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.12.sas

Document No.0986ba8e8038e9fvl.0 CONFIDENTIAL INFORMATION 6/1/658
Levothyroxine Dosage Form Proportions: 50 µg, 100 µg, and 200 µg Tablets in Fasted State
EMR 200125-002 EMR200125-002 Page 622 of 658

Hewett Rappo
EMR 200125-002

Figure 15.4.2.13 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total 79 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Source: listing 16.2.6.3

/project24/ephabit/210898_nacs/stats/versioncontrol/primary/scripts/program/main/3L programs/ Figures/Figure 15.4.2.13.scm

10BSC2014 00:20

Document No.0998040419490419110.0 CONFIDENTIAL INFORMATION 625718
Levothyroxine Dosage Form Proportion in total \(58\) (50 \(\mu g\), 100 \(\mu g\), and 200 \(\mu g\) Tablets) in Fasted State.

Figure 15.6.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-logarithmic Scale (for Total \(58\) values) (Safety Population)

Subject ID/Random Number:

![Graph](chart)

- Treatment A: 12 tablets of 50 \(\mu g\) of levothyroxine
- Treatment B: 6 tablets of 100 \(\mu g\) of levothyroxine
- Treatment C: 3 tablets of 200 \(\mu g\) of levothyroxine.

Source: [Listing](http://example.com)

/project/ep/blinded/0210HF_marc/stats/versioncontrol/primary/scripts/program/main/TFL_programs/Figures/15.6.2.12.sas

Document No.0000b46808508v1.0  CONFIDENTIAL INFORMATION

EMR200125-002 Page 623 of 658
Levothyroxine Dosage Form Proportions
EMR 200125-002
EMR 200125-002 Page 624 of 658

Merck Serono
EMR 200125-002

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total 75 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles](image)

- Subjects excluded from PK Population:
  - Treatment A: 12 tablets of 50 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine

Source: listing 16.2.5.3

/project24/cp/clinida/210898_marco/statistics/primary/simulcontrol/main/YPL programs/Figures/figure 15.4.2.12.sas

LODEC2014 08:28

Document No.099999de00819e9v1.0

CONFIDENTIAL INFORMATION
624658
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale for Total T3 values (Safety Population)

Subject ID/Randorn Number:

- Subjects excluded from PC Population:
  - Treatment A: 12 tablets of 50 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine

Source: Listing 16.2.5.2

/project/34/sp/blinded/0210898_merc/state/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.12.sas

Document No.00109a6085b09f1v1.0 CONFIDENTIAL INFORMATION 625638
Levothyroxine Dosage Form Proportion: 50 µg, 100 µg, and 200 µg Tablets in Fasted State

Subject ID/Random Number:

figure 15.4.2.13 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) [Safety Population]

Treatment:
- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Source: listing 15.2.5.3

/project24/log/linked/a210599_merc/stats/versioncontrol/primary/scripts/program/assign/WT programs/Figures/Figure 15.4.2.12.sas

10032014 00:20

Document No.09009b0c1085b0f1.0

CONFIDENTIAL INFORMATION 626658
Levothyroxine Dosage Form Proportion:
EMR 200125-002
Dosages (50 µg, 100 µg, and 200 µg Tablets) in Fasted State
EMR 200125-002 Page 627 of 658

Masco Serono
EMR 200125-602
Page 19 of 42
Confidential

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments]

- **Treatments**:
  - Treatment A: 12 tablets of 50 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine

Subject excluded from PK Population:

Treatments:
- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Source: listing 16.2.5.3

/project24/s2/blinded/s210989_merc/stats/versioncontrol/primary/scripts/program/main/CTL programs/Figure/figure 15.4.2.12.cse

Document No. 090012e8035ba9f-v1.0

CONFIDENTIAL INFORMATION

627058
Levothyroxine Dosage Form Proportions: 50 µg, 100 µg, and 200 µg Tablets in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total 73 values) (Safety Population)

Subject ID/Random Number:

Treatment A: Treatment B: Treatment C

10: Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.
Source: listing 16.2.5.3

/project24/ep/blinded/e210s09_merc/stats/versioncontrol/primary/scripts/program/main/FL programs/Figures/Figure 15.4.2.12.png
Levothyroxine Dosage Form Proportion: capsules (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-logarithmic Scale (for Total T₃ values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for levothyroxine treatments A, B, and C.](image)

Treatment: •••• Treatment A  •••• Treatment B  ▲▲▲▲ Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 16.2.5.2

/project24/wp/blinded/0316899_merc/stats/versioncontrol/primary/scripts/oxygen/1/ver/15.4.2.12.nsp  10/28/2014 00:20

Document No:0900beh4808ap9v1.0  CONFIDENTIAL
INFORMATION  028658
Figure 15.6.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 Values) [Safety Population]

Subject ID/Random Number:

Treatment:  ●●● Treatment A  ▲▲▲ Treatment B  ▲▲▲ Treatment C

8 Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: Listing 16.2.5.3

/project124/th/Blind/d/e210829 merc/stats/versioncontrol/primary/scripts/program/main/TL program/Figures/Figure 15.6.2.12.mps

IDRC2014 00:28

Document No. 6900hab8089bd0v1.0

CONFIDENTIAL
INFORMATION
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for individual T3 values](image)

Treatment: Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: listing 16.2.3.3

/project2/ep/blinded/h310898_parc/stats/versioncontrol/primary/scripts/program/wais/MTL programs/Figures/Figure 15.4.2.12.sas
Levothyroxine Dosage Form Proportion: Tablets (60 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 13.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 Values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

Subjects excluded from PK population:
Treatment A: 12 tablets of 50 µg of levothyroxine;
Treatment B: 6 tablets of 150 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 16.1.5.3

/project/124/ep/11/index/a110898_merc/stats/versioncontrol/primary/scripts/program/main/YTL programs/Figures/Figure 15.6.2.12.sse

Document No 09009ebe0885d9f4v1.0

CONFIDENTIAL INFORMATION

032628
Levothyroxine Dosage Form Proportions: 50 μg, 100 μg, and 200 μg Tablets in Fasted State

EMR 200125-002 Page 633 of 658

Merck Serono
EMR 200125-002

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

T3 (ng/mL) vs Time Point (h)

Treatment: •••• Treatment A  •••• Treatment B  ▲▲▲▲ Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: Listing 16.2.3.3

/project/24/examples/blinded/s210890_merc/stats/versioncontrol/primary/scripts/program/min/7FL_programs/Figures/figure 15.4.2.12.cwendung 10DE2014 00:28

Document No.0900b9e#083200Fv1.0 CONFIDENTIAL INFORMATION 633658
Levothyroxine Dosage Form Proportions

EMR200125-002 EMR200125-002 Page 63 of 658

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in semi-logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for different treatments.]

- Treatment A: 12 tablets of 50 μg of levothyroxine
- Treatment B: 6 tablets of 100 μg of levothyroxine
- Treatment C: 3 tablets of 200 μg of levothyroxine

Subjects excluded from PK population:
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.
Source: listing 16.2.5.3

/project24/ep/blinded/w210898_merc/stats/versioncontrol/primary/scripts/program/main/txt programs/figures/figure 15.4.2.12.aspx

Document No: 090000a0e08be9f1v1.0 CONFIDENTIAL INFORMATION 614658
Levothyroxine Dosage Form Properties - EMR 200125-002
(50 µg, 100 µg, and 200 µg Tablets) in Fasted State
EMR200125-002 Page 635 of 658

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph]

- Subjects excluded from PK Population:
  - Treatment A: 12 tablets of 50 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine.

Source: Listing 18.1.3.3

/project/ep/blinded/e21089f_nov/stats/versioncontrol/primary/scripts/program/main/TFL program/figures/figure 15.4.2.12.sas

Document No: 09000ab8085bf9v1.0

CONFIDENTIAL
INFORMATION

655658
Levotyroxine

Dosage Form Proportions:

EMR 200125-002

EMR200125-002 Page 636 of 658

Figure 15.4.2.17 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Rando. Number:

![Graph showing concentration-time profiles for different treatments]

- Treatment A: 12 tablets of 50 μg of levotyroxine
- Treatment B: 6 tablets of 100 μg of levotyroxine
- Treatment C: 3 tablets of 200 μg of levotyroxine

Source: Listing 16.2.5.3

/project24/wp/bliedex/c210899_merc/stats/versioncontrol/primary/scripts/program/main/ML programs/Figures/Figure
15.4.2.12.sas

10DEC2014 00:20

Document No.9909900899869v1.0

CONFIDENTIAL

INFORMATION
Levothyroxine Dosage Form Proportion tions (50 µg, 100 µg, and 200 µg Tablets) in Fasted State

Figure 15.4.2.12: Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Rando Number:

Treatment: ••••• Treatment A ••••• Treatment B ••••• Treatment C

0: Subjects excluded from PK Population:
Treatment A: 10 tablets of 50 µg of levothyroxine
Treatment B: 6 tablets of 100 µg of levothyroxine
Treatment C: 3 tablets of 200 µg of levothyroxine

Source: Listing 16.2.5.3

/project24/cp/blinded/e210898_mero/state/versioncontrol/primary/scripts/program/main/IFL programs/figure/figure 15.4.2.12.saw

1/DEC/2014 00:20

Document No.0900380830921.0 CONFIDENTIAL INFORMATION 627559
Levothyroxine Dosage Form Proportion: 50 μg, 100 μg, and 200 μg Tablets in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for Levothyroxine]

- Subjects excluded from PK Population:
  - Treatment A: 12 tablets of 50 μg of levothyroxine
  - Treatment B: 6 tablets of 100 μg of levothyroxine
  - Treatment C: 3 tablets of 200 μg of levothyroxine

Source: Listing 16.2.3.3

/project24/ep/blinded/s210808_merc/stats/versioncontrol/primary/scripts/program/main/TTL programs/Figures/Figure 15.4.2.12.sas

10DEC2014 09:28

Document No.090808eb088509Fv1.0 CONFIDENTIAL INFORMATION 035/658
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

- Subjects excluded from PK Population:
  - Treatment A: 12 tablets of 50 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine

Source: Listing 15.2.5.3

/project24/ap/blinded/e210898_marc/stats/versioncontrol/primary/scripts/program/main/TFL programs/Figures/Figure 15.4.2.12.sas

1/09/2014 00:29
Levothyroxine Dosage Form Proportions (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 15.4.2.18 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

- 0.1
- 1
- 10

Time Point (h)

2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 32 34 36 38 40 42 44 46 48 50 52 54 56 58

Treatment: • Treatment A  ▲ Treatment B  ▲ Treatment C

Subjects excluded from PK Population:

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine; Treatment C: 3 tablets of 200 μg of levothyroxine.

Source: listing 16.2.5.3

/project24/ap/blinded/0210998_p2r96aestatntcontrol/primary/scriptbinar/proc/main/TTL_script/main/Figures/figure 15.4.2.18.png
Levothyroxine Dosage Form Proportion: EMR200125-002
Leks (50 μg, 100 μg, and 200 μg Tablets) in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing concentration-time profiles for T3 levels in levothyroxine different dosage forms.]

- Treatment A: 12 tablets of 50 μg of levothyroxine
- Treatment B: 6 tablets of 100 μg of levothyroxine
- Treatment C: 3 tablets of 200 μg of levothyroxine

Source: listing 16.2.3.3

Document No.09008ebe008be9eFv10
CONFIDENTIAL INFORMATION 641658
Levotyroxine
Dosage Form Proportion: 50 μg, 100 μg, and 200 μg Tablets in Fasted State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

- Treatment: ● Treatment A  ● Treatment B  ● Treatment C

# Subjects excluded from PK population:
- Treatment A: 12 tablets of 50 μg of levotyroxine
- Treatment B: 6 tablets of 100 μg of levotyroxine
- Treatment C: 3 tablets of 200 μg of levotyroxine

Source: Listing 15.2.5.3

/project24/mg/blinded/121048_mecars/primary/scripts/primary/min/T3 programs/Figures/15.4.2.12.sas

Document No: 69090abc098509f1.0  CONFIDENTIAL INFORMATION
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Randon Number:

![Graph showing concentration-time profiles for different treatments.]

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Source: Listing 15.2.5.3

/project20/ep/blinded/22109598.merco/stats/versioncontrol/primary/scripts/program/saas/WL programs/Figures/Figure 15.4.2.12.res

10DEC2014 00:20
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population) Subject ID/Random Number

- Treatment A: 15 tablets of 50 μg of levothyroxine
- Treatment B: 6 tablets of 100 μg of levothyroxine
- Treatment C: 3 tablets of 200 μg of levothyroxine

Source: Listing 16.2.1.3
Figure 12.4.2.12 Concentration-Time Profiles: Individually Concentration versus Actual Time in Semi-logarithmic Scale
(for Top 3 values: Safety Population)

Subject ID/Random Number:

- Subjects excluded from PK Population:
  - Treatment A: 12 tablets of 50 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine

Source: Listing 16.2.5.1

/project24/ep/blinded/2719598_marc/stats/versioncontrol/primary/scripts/program/main/TWL programs/figures/figure
12.4.2.12.sas

Document No.6006bab8b08f96f10

CONFIDENTIAL
INFORMATION

EMR200125-002 Page 645 of 658
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Randon Number:

<table>
<thead>
<tr>
<th>Subject</th>
<th>Total T3 (ng/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Treatment A: 10 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Subjects excluded from PK Population.

Source: Listing 16.2.3.3

/project24/ep/blinded/c310898_marc/stats/versioncontrol/primary/scripts/program/main/T1 programs/figures/figure 15.4.2.12.sas

10/02/2014 09:20
Levothyroxine Dosage Form Proportion: EMR 200125-002 

Emerson EMR 200125-002 Page 647 of 658

Merck Serono
 EMR 200125-002

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)

Subject ID/Random Number:

![Graph showing Concentration-Time Profiles](image)

- Treatment: Treatment A
- Treatment B
- Treatment C

# Subjects excluded from PK Population:
- Treatment A: 12 tablets of 50 μg of levothyroxine
- Treatment B: 6 tablets of 100 μg of levothyroxine
- Treatment C: 3 tablets of 200 μg of levothyroxine

Source: Listing 16.2.5.3

/project24/sp/olindex/e210899_mer/s-free/stats/versioncontrol/primary/scripts/program/main/TPL programs/Figure 15.4.2.12.sas

13DEC2014 00:25

Document No:9900bah8048bf9v1.0

CONFIDENTIAL INFORMATION
Levotirothroxine Dosage Form Proportions
EMR 200125-002 State

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population) Subject ID/Random Number:

Treatment: A- - - - - Treatment C

Subjects excluded from PK Population:
Treatment A: 12 tablets of 50 μg of levotirothroxine; Treatment B: 6 tablets of 100 μg of levotirothroxine; Treatment C: 3 tablets of 200 μg of levotirothroxine.

Source: Listing 16.2.5.3

/projeky24/ep/blinded/w510998_merc/stats/versioncontrol/primary/scripts/program/main/TEG programs/Figures/Figure 15.4.2.12.sas

15DEC2014 00:20

Document No.0000504008356efv1.0 CONFIDENTIAL INFORMATION 648:658
Levothyroxine Dosage Form Proprieties: 
EMR 200125-002
State EMR200125-002 Page 649 of 658

Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total T3 values) (Safety Population)
Subject ID/Sarnos Number:

![Graph showing concentration-time profiles for different treatments.]

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Subjects excluded from PK Populations:

- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

Source: listing 16.2.5.3

/project24/wp/blinded/v210899_merc/stats/versioncontrol/primary/scripts/program/main/FIG programs/figures/figure 15.4.2.12.sas

Document No.0900dab8005b69v1.0 CONFIDENTIAL INFORMATION 649658
Figure 15.4.2.12 Concentration-Time Profiles: Individual Concentration versus Actual Time in Semi-Logarithmic Scale (for Total 13 values) (Safety Population)

Subject ID/Randon Number:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Time Point (h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>0 1 2 3 4 5 6</td>
</tr>
<tr>
<td>B</td>
<td>1 1 1 1 1 1 1</td>
</tr>
<tr>
<td>C</td>
<td>1 1 1 1 1 1 1</td>
</tr>
</tbody>
</table>

- Subjects excluded from PK Population:
  - Treatment A: 12 tablets of 30 µg of levothyroxine
  - Treatment B: 6 tablets of 100 µg of levothyroxine
  - Treatment C: 3 tablets of 200 µg of levothyroxine

Source: listing 16.2.5.3

/project24/exp/bledad/a210908_marc/state/versioncontrol/primary/scripts/program/main/TEF programs/Figures/15.4.2.12.pdf
Figure 15.4.3.1.1 Boxplot: Cmax and AUC0-72 for Total 74 (Pharmacokinetic Population)

Parameter: Cmax (ng/mL)

Subjects are excluded from the PK Population.
Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine;
Subjects were excluded from the PK Population.
Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

/Project24/op/blinded/c210898_nerc/stats/versioncontrol/primary/scripts/program/min/CCF program/figures/figure 15.4.1.1.1.png

Document No.0999abc805b9f1v1.9
CONFIDENTIAL
INFORMATION
632658
Figure 15.4.3.1.2 Boxplot: Baseline Adjusted Cmax and Baseline Adjusted AUC0-72 for Total T4 (Pharmacokinetic Population)

Parameter: Baseline Adjusted Cmax (ng/mL)

Subjects

- ... were excluded from the PK Population.

Treatment A: 12 tablets of 50 µg of levothyroxine; Treatment B: 6 tablets of 100 µg of levothyroxine; Treatment C: 3 tablets of 200 µg of levothyroxine.

/project24/wp/blindod/e210698_merz/stats/versioncontrol/primary/scripts/program/main/T4I programs/Figures/Figure 15.4.3.1.2.xas
Levothyroxine Dosage Form Proportion: \[ \text{EMR 200125-002} \]

<table>
<thead>
<tr>
<th>Groups</th>
<th>Levothyroxine Doses (50 ( \mu g ), 100 ( \mu g ), and 200 ( \mu g ) Tablets) in Fasted State</th>
<th>EMR200125-002 Page 654 of 658</th>
</tr>
</thead>
</table>

Figure 15.4.3.1.2 Boxplot: Baseline Adjusted Cmax and Baseline Adjusted AUC0-72 for Total 74 (Pharmacokinetic Population) Parameter: Baseline Adjusted AUC0-72 (hr\( \cdot \)ng/mL)

Subjects were excluded from the PK Population.

Treatment A: 12 tablets of 50 \( \mu g \) levothyroxine; Treatment B: 6 tablets of 100 \( \mu g \) of levothyroxine; Treatment C: 3 tablets of 200 \( \mu g \) of levothyroxine;

/doc/a3b3239f0a/stats/versioncontrol/primary/scripts/program/min/TTL programs/Figures/Figure 15.4.3.1.2.png

10/5/2014 06:08

Document No.09009abc80856e9f1210.0 CONFIDENTIAL INFORMATION 65458
Figure 15.4.3.1.3 Boxplot: Baseline Adjusted AUC0-48 for Total T4 (Pharmacokinetic Population)

Parameter: Baseline Adjusted AUC0-48 (hr\*ug/mL)

Subjects were excluded from the PK Population.

Treatment A: 12 tablets of 50 μg of levothyroxine; Treatment B: 6 tablets of 100 μg of levothyroxine;
Treatment C: 3 tablets of 200 μg of levothyroxine;

/project24/ep/blinded/e010899_pezzo/stats/versioncontrol/primary/scripts/program/main/TLW_programs/Figures/Figure 15.4.3.1.3.888

18DEC2014 05:00
Figure 15.4.3.1.4 Boxplot: Cmax and AUC0-48 for Total T3 (Pharmacokinetic Population)

Parameter: Cmax [ng/mL]

Subjects were excluded from the PK Population.

Treatment A: 12 tablets of 30 µg of levothyroxine;
Treatment B: 6 tablets of 100 µg of levothyroxine;
Treatment C: 3 tablets of 200 µg of levothyroxine;

/project24/np/blinded/e21089b_new/stats/versioncontrol/primary/scripts/program/main/T3 program/figures/figure
15.4.3.1.4_scc

1808226C3 06:08

Document No.8900abc80889e95v1.0 CONFIDENTIAL INFORMATION 656638
Figure 15.4.3.1.4 Boxplot: Cmax and AUC0-48 for Total T3 (Pharmacokinetic Population)

Parameter: AUC0-48 (hr*ng/mL)

Subjects:
- Treatment A: 12 tablets of 50 µg of levothyroxine
- Treatment B: 6 tablets of 100 µg of levothyroxine
- Treatment C: 3 tablets of 200 µg of levothyroxine

The boxplot shows the distribution of AUC0-48 for the treatments A, B, and C.
15.5 Pharmacodynamic Data

There were no pharmacodynamic assessments performed during this trial.